



2022 Vol.16(3)



TB ALERT

(a monthly publication from NIRT Library)

ICMR-National Institute for Research in Tuberculosis



1. A NK, Jarti M, Haida MZ, Aouroud M, Errami AA, Oubaha S, et al. [Multinodular splenomegaly revealing multifocal, splenic and spinal tuberculosis: a case report]. *Pan Afr Med J*. 2021;40:230. <https://www.ncbi.nlm.nih.gov/pubmed/35145592>.
2. Abrahams JS, Weigand MR, Ring N, MacArthur I, ETTY J, Peng S, et al. Towards comprehensive understanding of bacterial genetic diversity: large-scale amplifications in *Bordetella pertussis* and *Mycobacterium tuberculosis*. *Microb Genom*. 2022;8(2). <https://www.ncbi.nlm.nih.gov/pubmed/35143385>.
3. Agarwal S, Tiwari P, Deep A, Kidwai S, Gupta S, Thakur KG, et al. Corrigendum to: System-Wide Analysis Unravels the Differential Regulation and In Vivo Essentiality of Virulence-Associated Proteins B and C Toxin-Antitoxin Systems of *Mycobacterium tuberculosis*. *J Infect Dis*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35147695>.
4. Ahlawat P, Upadhyay P. A Crucial Aftershock in Pulmonary Tuberculosis Survivors: A Case Report. *Cureus*. 2022;14(1):e20986. <https://www.ncbi.nlm.nih.gov/pubmed/35154962>.
5. Alam A, Abubaker Bagabir H, Sultan A, Siddiqui MF, Imam N, Alkhanani MF, et al. An Integrative Network Approach to Identify Common Genes for the Therapeutics in Tuberculosis and Its Overlapping Non-Communicable Diseases. *Front Pharmacol*. 2021;12:770762. <https://www.ncbi.nlm.nih.gov/pubmed/35153741>.
6. Alrashed RF, Alkhuwaylidi AA, Aldashash KA, Albati NA, Algarni AA, Almodhaiberi H, et al. Peritoneal Tuberculosis in a Young Healthy Male Resembling Intra-Abdominal Malignancy. *Cureus*. 2021;13(12):e20677. <https://www.ncbi.nlm.nih.gov/pubmed/35106218>.
7. Arfa A, Omar N, Bano K, Savage NM. Disseminated *Mycobacterium tuberculosis*: An Unusual Presentation with Associated Hemophagocytic Lymphohistiocytosis. *Case Rep Hematol*. 2022;2022:4669025. <https://www.ncbi.nlm.nih.gov/pubmed/35127182>.
8. Arriaga MB, Araujo-Pereira M, Barreto-Duarte B, Sales C, Miguez-Pinto JP, Nogueira EB, et al. Prevalence and Clinical Profiling of Dysglycemia and HIV Infection in Persons With Pulmonary Tuberculosis in Brazil. *Front Med (Lausanne)*. 2021;8:804173. <https://www.ncbi.nlm.nih.gov/pubmed/35127760>.
9. Arrieta O, Molina-Romero C, Cornejo-Granados F, Marquina-Castillo B, Aviles-Salas A, Lopez-Leal G, et al. Clinical and pathological characteristics associated with the presence of the IS6110 *Mycobacterium tuberculosis* transposon in neoplastic cells from non-small cell lung cancer patients. *Sci Rep*. 2022;12(1):2210. <https://www.ncbi.nlm.nih.gov/pubmed/35140255>.
10. Asgharzadeh M, Taghinejad Z, Mahdaviipoor B, Asgharzadeh V, Kafil HS, Rashedi J. Mixed tuberculosis infections in Northwest of Iran. *Infect Med*. 2021;29(4):583-8. <https://www.ncbi.nlm.nih.gov/pubmed/35146368>.
11. Awasthi K, Kootimole CN, Aravind A, Prasad TSK. Data-Independent Acquisition Approach to Proteome: A Case Study and a Spectral Library for Mass Spectrometry-Based Investigation of *Mycobacterium tuberculosis*. *OMICS*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35099291>.

12. Babu Sait MR, Koliwer-Brandl H, Stewart JA, Swarts BM, Jacobsen M, Ioerger TR, et al. PPE51 mediates uptake of trehalose across the mycomembrane of Mycobacterium tuberculosis. *Sci Rep.* 2022;12(1):2097. <https://www.ncbi.nlm.nih.gov/pubmed/35136132>.
13. Baleguli V, Rizvi S, Varghese M, Ilyas J. A Rare Cause of Esophageal Dysphagia - Secondary Esophageal Tuberculosis. *Cureus.* 2022;14(1):e21019. <https://www.ncbi.nlm.nih.gov/pubmed/35154989>.
14. Berg A, Clary J, Hanna D, Nuermberger E, Lenaerts A, Ammerman N, et al. Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative Database. *Antimicrob Agents Chemother.* 2022:AAC0179321. <https://www.ncbi.nlm.nih.gov/pubmed/35099274>.
15. Birhanu AG, Gomez-Munoz M, Kalayou S, Riaz T, Lutter T, Yimer SA, et al. Proteome Profiling of Mycobacterium tuberculosis Cells Exposed to Nitrosative Stress. *ACS Omega.* 2022;7(4):3470-82. <https://www.ncbi.nlm.nih.gov/pubmed/35128256>.
16. Calnan M, Moran A, Jassim AlMossawi H. Maintaining essential tuberculosis services during the COVID-19 pandemic, Philippines. *Bull World Health Organ.* 2022;100(2):127-34. <https://www.ncbi.nlm.nih.gov/pubmed/35125537>.
17. Caren GJ, Iskandar D, Pitaloka DAE, Abdulah R, Suwantika AA. COVID-19 Pandemic Disruption on the Management of Tuberculosis Treatment in Indonesia. *J Multidiscip Healthc.* 2022;15:175-83. <https://www.ncbi.nlm.nih.gov/pubmed/35115781>.
18. Carless MA, Schlesinger LS. Mycobacterium tuberculosis remodels host transcriptome. *Nat Microbiol.* 2022;7(2):189-90. <https://www.ncbi.nlm.nih.gov/pubmed/35102305>.
19. Carr BZ, Briganti EM, Musemburi J, Jenkin GA, Denholm JT. Effect of chronic kidney disease on all-cause mortality in tuberculosis disease: an Australian cohort study. *BMC Infect Dis.* 2022;22(1):116. <https://www.ncbi.nlm.nih.gov/pubmed/35109801>.
20. Cerejeira A, Canelas G, Vide J, Duro R, Azevedo F, Magina S. Cavitory pulmonary tuberculosis during treatment with guselkumab. *J Eur Acad Dermatol Venereol.* 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35138650>.
21. Chandra P, Coullon H, Agarwal M, Goss CW, Philips JA. Macrophage global metabolomics identifies cholestenone as host/pathogen cometabolite present in human Mycobacterium tuberculosis infection. *J Clin Invest.* 2022;132(3). <https://www.ncbi.nlm.nih.gov/pubmed/35104812>.
22. Chengalroyen MD, Mason MK, Borsellini A, Tassoni R, Abrahams GL, Lynch S, et al. DNA-Dependent Binding of Nargenicin to DnaE1 Inhibits Replication in Mycobacterium tuberculosis. *ACS Infect Dis.* 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35143160>.
23. Chinese Society for Tuberculosis CMA. [Expert opinions on clinical application of interferon-gamma release assay of Mycobacterium tuberculosis (2021 edition)]. *Zhonghua Jie He He Hu Xi Za Zhi.* 2022;45(2):143-50. <https://www.ncbi.nlm.nih.gov/pubmed/35135083>.

24. Chitpim N, Jittikoon J, Udomsinprasert W, Mahasirimongkol S, Chaikledkaew U. Cost-Utility Analysis of Molecular Testing for Tuberculosis Diagnosis in Suspected Pulmonary Tuberculosis in Thailand. *Clinicoecon Outcomes Res.* 2022;14:61-73. <https://www.ncbi.nlm.nih.gov/pubmed/35140485>.
25. Choi PJ, Lu GL, Sutherland HS, Giddens AC, Franzblau SG, Cooper CB, et al. Synthetic studies towards isomeric pyrazolopyrimidines as potential ATP synthesis inhibitors of Mycobacterium tuberculosis. Structural correction of reported N-(6-(2-(dimethylamino)ethoxy)-5-fluoropyridin-3-yl)-2-(4-fluorophenyl)-5-(trifluoromethyl)pyrazolo[1,5- α]pyrimidin-7-amine. *Tetrahedron Lett.* 2022;90:None. <https://www.ncbi.nlm.nih.gov/pubmed/35140452>.
26. Choudhary NK, Samanta RP, Bhargava R. Rare Presentation of Tuberculosis Mimicking Malignancy. *Cureus.* 2021;13(12):e20841. <https://www.ncbi.nlm.nih.gov/pubmed/35141090>.
27. Clarke C, Cooper DV, Miller MA, Goosen WJ. Detection of Mycobacterium tuberculosis complex DNA in oronasal swabs from infected African buffaloes (*Syncerus caffer*). *Sci Rep.* 2022;12(1):1834. <https://www.ncbi.nlm.nih.gov/pubmed/35115633>.
28. da Silva EH, Lima E, Dos Santos TR, Padoveze MC. Prevalence and incidence of tuberculosis in health workers: a systematic review of the literature. *Am J Infect Control.* 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35108578>.
29. Dastgir G, Majeed MI, Nawaz H, Rashid N, Raza A, Ali MZ, et al. Surface-enhanced Raman spectroscopy of polymerase chain reaction (PCR) products of Rifampin resistant and susceptible tuberculosis patients. *Photodiagnosis Photodyn Ther.* 2022;38:102758. <https://www.ncbi.nlm.nih.gov/pubmed/35158074>.
30. Debelu T, Abunna F, Mamo Kassa G, Ameni G. Epidemiology of Avian Tuberculosis in Selected Districts of Oromia Region, Ethiopia. *Vet Med Int.* 2022;2022:6933701. <https://www.ncbi.nlm.nih.gov/pubmed/35126991>.
31. Del Rosario RCH, Poschmann J, Lim C, Cheng CY, Kumar P, Riou C, et al. Histone acetylome-wide associations in immune cells from individuals with active Mycobacterium tuberculosis infection. *Nat Microbiol.* 2022;7(2):312-26. <https://www.ncbi.nlm.nih.gov/pubmed/35102304>.
32. Derendinger B, de Vos M, Pillay S, Venter R, Metcalfe J, Ghebrekristos Y, et al. Frequent Suboptimal Thermocycler Ramp Rate Usage Negatively Impacts GenoType MTBDRsl VER 2.0 Performance for Second-Line Drug-Resistant Tuberculosis Diagnosis. *J Mol Diagn.* 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35108607>.
33. Diriba K, Churiso G. The prevalence of Mycobacterium tuberculosis using Gene Xpert among tuberculosis suspected patients in Gedeo Zone, Southern Ethiopia. *Eur J Med Res.* 2022;27(1):24. <https://www.ncbi.nlm.nih.gov/pubmed/35151350>.
34. Du X, Ou Y, Luo W, Jiang G, Qin W, Zhu Y. Evaluation of the efficacy of OLIF combined posterior internal fixation for single-segment lumbar tuberculosis: a single-center retrospective cohort study. *BMC Surg.* 2022;22(1):54. <https://www.ncbi.nlm.nih.gov/pubmed/35152902>.

35. Engin G, Yirgin K, Kandemir H. Extrapulmonary Tuberculosis Mimics Diffuse Metastatic Disease: A Case Report. *Indian J Radiol Imaging*. 2021;31(4):1039-42. <https://www.ncbi.nlm.nih.gov/pubmed/35136525>.
36. Essone PN, Adegbite BR, Mbadanga MJM, Mbouna AV, Lotola-Mougeni F, Alabi A, et al. Creatine kinase-(MB) and hepcidin as candidate biomarkers for early diagnosis of pulmonary tuberculosis: a proof-of-concept study in Lambarene, Gabon. *Infection*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35133607>.
37. Fan Z, Tong N, Zhuang Z, Ma C, Ma J, Ju J, et al. Medium optimization and subsequent fermentative regulation enabled the scaled-up production of anti-tuberculosis drug leads ilamycin-E1/E2. *Biotechnol J*. 2022:e2100427. <https://www.ncbi.nlm.nih.gov/pubmed/35098690>.
38. Fiorella C. Treatment with secukinumab for plaque psoriasis in patients with infectious comorbidities and latent tuberculosis: A multi-case report analysis. *Clin Case Rep*. 2022;10(1):e05302. <https://www.ncbi.nlm.nih.gov/pubmed/35127089>.
39. Frontiers Production O. Erratum: Cefdinir and beta-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis. *Front Pharmacol*. 2022;13:849039. <https://www.ncbi.nlm.nih.gov/pubmed/35153803>.
40. Gaidarov GM, Apkhanova NS, Alekseeva NY, Alekseevskaya TI, Dushina EV. [The trends of spreading of tuberculosis combined with HIV-infection among population the Siberian Federal Okrug]. *Probl Sotsialnoi Gig Zdravookhranennii i Istor Med*. 2022;30(1):97-101. <https://www.ncbi.nlm.nih.gov/pubmed/35157387>.
41. Golichenari B, Yari S, Tasbiti AH, Behravan J, Vaziri F, Ghazvini K. First conjugation directed traverse of gene cassettes harboring alpha1,3GT from fast-growing Mycobacterium smegmatis mc(2) 155 to slow-growing pathogen Mycobacterium tuberculosis H37Rv, presumably opening up new scopes in tuberculosis treatment. *Enzyme Microb Technol*. 2022;156:110003. <https://www.ncbi.nlm.nih.gov/pubmed/35149427>.
42. Gomez M, Ahmed M, Das S, McCollum J, Mellett L, Swanson R, et al. Development and Testing of a Spray-Dried Tuberculosis Vaccine Candidate in a Mouse Model. *Front Pharmacol*. 2021;12:799034. <https://www.ncbi.nlm.nih.gov/pubmed/35126135>.
43. Guirelli AO, Bispo TR, Colpas DR, de Campos IB, Chimara E, Cergole-Novella MC, et al. Tuberculosis/COVID-19 co-infection detected in a single sputum sample using a rapid molecular test. *Braz J Microbiol*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35107805>.
44. Gunduz Gurkan C, Sekerbey H, Babalik A. Disseminated Tuberculosis: A 3-Year Case-Series Experience in a Tertiary Care Center. *Turk Thorac J*. 2021;22(5):358-63. <https://www.ncbi.nlm.nih.gov/pubmed/35110207>.
45. Guo S, Lei S, Li J, Li L, Chen H, Chongsuvivatwong V. Gradient association between pulmonary tuberculosis and diabetes mellitus among households with a tuberculosis case: a contact tracing-based study. *Sci Rep*. 2022;12(1):1854. <https://www.ncbi.nlm.nih.gov/pubmed/35115583>.

46. Gupta S, Kumar C, Shrivastava K, Chauhan V, Singh A, Arora R, et al. Whole genome sequencing of isoniazid monoresistant clinical isolates of Mycobacterium tuberculosis reveals novel genetic polymorphisms. *Tuberculosis (Edinb)*. 2022;133:102173. <https://www.ncbi.nlm.nih.gov/pubmed/35158296>.
47. Harris RC, Quaife M, Weerasuriya C, Gomez GB, Sumner T, Bozzani F, et al. Cost-effectiveness of routine adolescent vaccination with an M72/AS01E-like tuberculosis vaccine in South Africa and India. *Nat Commun*. 2022;13(1):602. <https://www.ncbi.nlm.nih.gov/pubmed/35105879>.
48. Huang D, Jin S, Zhang W, Zhou X, Li R, Chen K, et al. A rare case of coexistence of tuberculosis verrucosa cutis and pulmonary tuberculosis. *Postepy Dermatol Alergol*. 2021;38(6):1124-6. <https://www.ncbi.nlm.nih.gov/pubmed/35126028>.
49. Ippolito D, Boniotti MB, Fiasconaro M, Fontana S, Boifava M, Pruiti Ciarello F, et al. Development and evaluation of a multi-antigen serological assay for the intra-vitam diagnosis of Tuberculosis caused by Mycobacterium bovis in pigs. *J Immunol Methods*. 2022;503:113234. <https://www.ncbi.nlm.nih.gov/pubmed/35149055>.
50. Jacobs R, Awoniyi DO, Baumann R, Stanley K, McAnda S, Kaempfer S, et al. Concurrent evaluation of cytokines improves the accuracy of antibodies against Mycobacterium tuberculosis antigens in the diagnosis of active tuberculosis. *Tuberculosis (Edinb)*. 2022;133:102169. <https://www.ncbi.nlm.nih.gov/pubmed/35121532>.
51. James R, Theron G, Cobelens F, Engel N. Framing the detection of incipient tuberculosis infection: A qualitative study of political prioritisation. *Trop Med Int Health*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35156273>.
52. Jia H, Chu H, Dai G, Cao T, Sun Z. Rv1258c acts as a drug efflux pump and growth controlling factor in Mycobacterium tuberculosis. *Tuberculosis (Edinb)*. 2022;133:102172. <https://www.ncbi.nlm.nih.gov/pubmed/35158297>.
53. Jiang G, Zhu Y, Zhang M, Qin W, Xiong T, Ou Y. The risk factors of the postoperative poor wound healing in spinal tuberculosis patients: A single centre retrospective cohort study. *Int Wound J*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35132769>.
54. Jiang X, Zeng H, Duan C, Hu Q, Wu Q, Yu Y, et al. One-pot synthesis of stable and functional hydrophilic CsPbBr₃ perovskite quantum dots for "turn-on" fluorescence detection of Mycobacterium tuberculosis. *Dalton Trans*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35147147>.
55. Joslyn LR, Linderman JJ, Kirschner DE. A virtual host model of Mycobacterium tuberculosis infection identifies early immune events as predictive of infection outcomes. *J Theor Biol*. 2022;111042. <https://www.ncbi.nlm.nih.gov/pubmed/35114195>.
56. Kale A, Patil PS, Kulkarni S, Tandon S, Deodhar K. 'Hepatic tuberculosis: a sheep in wolf's clothing'. Author response. *Hepatol Int*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35141863>.

57. Katana GG, Ngari M, Maina T, Sanga D, Abdullahi OA. Tuberculosis poor treatment outcomes and its determinants in Kilifi County, Kenya: a retrospective cohort study from 2012 to 2019. *Arch Public Health*. 2022;80(1):48. <https://www.ncbi.nlm.nih.gov/pubmed/35123570>.
58. Katrak SS, Li R, Reynolds S, Marks SM, Probst JR, Chorba T, et al. Association of Tumor Necrosis Factor alpha Inhibitor Use with Diagnostic Features and Mortality of Tuberculosis in the United States, 2010-2017. *Open Forum Infect Dis*. 2022;9(2):ofab641. <https://www.ncbi.nlm.nih.gov/pubmed/35106318>.
59. Kaul S, Jakhar D, Mehta S, Singal A. Cutaneous tuberculosis. Part II: Complications, diagnostic workup, histopathological features, and treatment. *J Am Acad Dermatol*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35149148>.
60. Kaul S, Kaur I, Mehta S, Singal A. Cutaneous tuberculosis. Part I: Pathogenesis, classification, and clinical features. *J Am Acad Dermatol*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35149149>.
61. Kavadiachanda C, Adarsh MB, Ajmani S, Maccora I, Balan S, Ramanan AV, et al. Tuberculosis in Children with Rheumatic Diseases Treated with Biologic Disease-Modifying Anti-Rheumatic Drugs. *Mediterr J Rheumatol*. 2021;32(4):290-315. <https://www.ncbi.nlm.nih.gov/pubmed/35128322>.
62. Kebede F, Tarekegn H, Molla M, Jara D, Abate A. Incidence and Predictors of Pulmonary Tuberculosis among Children Who Received Antiretroviral Therapy (ART), Northwest Ethiopia: A Multicenter Historical Cohorts Study 2009-2019. *J Trop Med*. 2022;2022:9925693. <https://www.ncbi.nlm.nih.gov/pubmed/35132323>.
63. Khan Z, Jugnarain D, Mahamud B, Gupta A, Patel S, Mlawa G. Systemic Manifestation of Miliary Tuberculosis in Patient With Advanced Diabetic Retinopathy Presenting With Electrolyte Imbalance, Seizures, and Adrenal Insufficiency. *Cureus*. 2022;14(1):e21047. <https://www.ncbi.nlm.nih.gov/pubmed/35155014>.
64. Kheirandish M, Catanzaro D, Crudu V, Zhang S. Integrating landmark modeling framework and machine learning algorithms for dynamic prediction of tuberculosis treatment outcomes. *J Am Med Inform Assoc*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35139541>.
65. Kilic L, Altin S, Gonenc Ortakoylu M, Kanmaz ZD, Tutar T, Ozkan GZ. Co-infection of COVID-19 and Tuberculosis. *Turk Thorac J*. 2022;23(1):58-62. <https://www.ncbi.nlm.nih.gov/pubmed/35110202>.
66. Kochlamazashvili M, Butsashvili M, Kajaia M, Gulbiani L, Urtkmedidze I, Khonelidze I. Gender Related Barriers to Tuberculosis in Georgia. *Georgian Med News*. 2022(322):48-52. <https://www.ncbi.nlm.nih.gov/pubmed/35134759>.
67. Kommi S, Ajit N, Sricharan KB, Priya RR, Mohan VK, Kalawat T. An Uncommon Presentation of Extrapulmonary Tuberculosis Masquerading as Ovarian Malignancy in a Young Female. *Indian J Nucl Med*. 2021;36(4):437-40. <https://www.ncbi.nlm.nih.gov/pubmed/35125765>.

68. Kone B, Somboro AM, Kone M, Holl JL, Baya B, Dabitaio D, et al. Molecular epidemiology and genetic diversity of Mycobacterium tuberculosis complex in referral health centers of Bamako, Mali: What is new? *Int J Infect Dis.* 2022;117:204-11. <https://www.ncbi.nlm.nih.gov/pubmed/35134562>.
69. Kumar P, Jena A, Birda CL, Singh H, Gupta P, Prasad KK, et al. Safety and efficacy of non-fluoroscopic endoscopic dilatation of gastrointestinal tuberculosis related strictures. *BMC Gastroenterol.* 2022;22(1):60. <https://www.ncbi.nlm.nih.gov/pubmed/35148672>.
70. Kurtulus S, Can R. The Effect of Environmental Exposures on the Diagnosis of Tuberculosis in Syrian Refugees. *Turk Thorac J.* 2021;22(6):489-93. <https://www.ncbi.nlm.nih.gov/pubmed/35110266>.
71. Laxmeshwar C, Das M, Mathur T, Israni T, Jha S, Iyer A, et al. Psychiatric comorbidities among patients with complex drug-resistant tuberculosis in Mumbai, India. *PLoS One.* 2022;17(2):e0263759. <https://www.ncbi.nlm.nih.gov/pubmed/35148328>.
72. Leong KWC, Gautam SS, Pradhan M, Singh YI, Kc R, Rajbhandari SK, et al. Comparative genomic analyses of multi-drug resistant Mycobacterium tuberculosis from Nepal and other geographical locations. *Genomics.* 2022;114(2):110278. <https://www.ncbi.nlm.nih.gov/pubmed/35143885>.
73. Li M, Qiu Y, Guo M, Zhang S, Wang G, Wang Y, et al. Investigation on the cause of recurrent tuberculosis in a rural area in China using whole-genome sequencing: A retrospective cohort study. *Tuberculosis (Edinb).* 2022;133:102174. <https://www.ncbi.nlm.nih.gov/pubmed/35124543>.
74. Li ZB, Shi LY, Han YS, Chen J, Zhang SQ, Chen JX, et al. Pyridoxal phosphate, pyridoxamine phosphate, and folic acid based on ceRNA regulatory network as potential biomarkers for the diagnosis of pulmonary tuberculosis. *Infect Genet Evol.* 2022;99:105240. <https://www.ncbi.nlm.nih.gov/pubmed/35150890>.
75. Librianto D, Saleh I, Ipang F, Aprilya D. Freehand Pedicle Screw Insertion in Spondylitis Tuberculosis Kyphosis Correction Using Cantilever Method: A Breach Rate Analysis of 168 Consecutive Screws. *Orthop Res Rev.* 2022;14:17-24. <https://www.ncbi.nlm.nih.gov/pubmed/35115848>.
76. Lin HC, Yu MC, Putri DU, Tsai YS, Chen JH, Lee CH. Minimizing nephrotoxicity during multidrug-resistant tuberculosis treatment by the stepwise de-escalation of second-line injectables dosing intervals. *Clin Microbiol Infect.* 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35124260>.
77. Liu K, Chen S, Zhang Y, Li T, Xie B, Wang W, et al. Tuberculosis burden caused by migrant population in Eastern China: evidence from notification records in Zhejiang Province during 2013-2017. *BMC Infect Dis.* 2022;22(1):109. <https://www.ncbi.nlm.nih.gov/pubmed/35100983>.
78. Liu P, Liu Y, Wang Y, Hao S, Qin Y. Assessing the diagnostic accuracy of the Xpert MTB/RIF assay in detecting epididymal tuberculosis. *Eur J Clin Microbiol Infect Dis.* 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35128582>.

79. Liu Z, Xu Z, Zhang Y, Wang X, Zhang Z, Jiang D, et al. Endoscopy-assisted anterior cervical debridement combined with posterior fixation and fusion for the treatment of upper cervical spine tuberculosis: a retrospective feasibility study. *BMC Musculoskelet Disord.* 2022;23(1):126. <https://www.ncbi.nlm.nih.gov/pubmed/35135516>.
80. Lu N, Yang Y, Li X, Li J, Cheng J, Lv Z, et al. The Protective Action of Piperlongumine Against Mycobacterial Pulmonary Tuberculosis in Its Mitigation of Inflammation and Macrophage Infiltration in Male BALB/c Mice. *J Vet Res.* 2021;65(4):431-40. <https://www.ncbi.nlm.nih.gov/pubmed/35111996>.
81. Ma J, Jiang G, Ma Q, Wang H, Du M, Wang C, et al. Rapid detection of airborne protein from Mycobacterium tuberculosis using a biosensor detection system. *Analyst.* 2022;147(4):614-24. <https://www.ncbi.nlm.nih.gov/pubmed/35118485>.
82. Ma SW, Wang JR, Zhu YM. [Drug selection for simultaneous treatment of tuberculosis combined with hepatitis C virus infection]. *Zhonghua Gan Zang Bing Za Zhi.* 2022;30(1):113-6. <https://www.ncbi.nlm.nih.gov/pubmed/35152682>.
83. Mademilov M, Mirzalieva G, Yusuf ZK, Orme MW, Bourne C, Akylbekov A, et al. What should pulmonary rehabilitation look like for people living with post-tuberculosis lung disease in the Bishkek and Chui region of the Kyrgyz Republic? A qualitative exploration. *BMJ Open.* 2022;12(2):e053085. <https://www.ncbi.nlm.nih.gov/pubmed/35121602>.
84. Maison DP. Tuberculosis pathophysiology and anti-VEGF intervention. *J Clin Tuberc Other Mycobact Dis.* 2022;27:100300. <https://www.ncbi.nlm.nih.gov/pubmed/35111979>.
85. Makabayi-Mugabe R, Musaaazi J, Zawedde-Muyanja S, Kizito E, Namwanje H, Aleu P, et al. Developing a patient-centered community-based model for management of multi-drug resistant tuberculosis in Uganda: a discrete choice experiment. *BMC Health Serv Res.* 2022;22(1):154. <https://www.ncbi.nlm.nih.gov/pubmed/35123467>.
86. Malik I, Cizmarik J, Kovac G, Pechacova M, Hudecova L. Telacebec (Q203): Is there a novel effective and safe anti-tuberculosis drug on the horizon? *Ceska Slov Farm.* 2021;70(5):164-71. <https://www.ncbi.nlm.nih.gov/pubmed/35114793>.
87. Mannebach K, Dressel A, Eason L. Pediatric tuberculosis in India: Justice and human rights. *Public Health Nurs.* 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35152480>.
88. Marahatta SB, Yadav RK, Baral S, Aryal N, Paudel S, Shah NP, et al. Barriers to Treatment Compliance of Directly Observed Treatment Shortcourse among Pulmonary Tuberculosis Patients. *J Nepal Health Res Counc.* 2021;19(3):450-9. <https://www.ncbi.nlm.nih.gov/pubmed/35140414>.
89. Marfil MJ, Barandiaran S, Zumarraga MJ, Germani L, Faccini T, Linares M, et al. Mycobacterium tuberculosis infection in a free-ranging urban dog from Argentina. *Vet Res Commun.* 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35133571>.

90. Metwally AS, El-Sheikh SMA, Galal AAA. The impact of diabetes mellitus on the pharmacokinetics of rifampicin among tuberculosis patients: A systematic review and meta-analysis study. *Diabetes Metab Syndr*. 2022;16(2):102410. <https://www.ncbi.nlm.nih.gov/pubmed/35144181>.
91. Micheni LN, Kassaza K, Kinyi H, Ntulume I, Bazira J. Detection of Mycobacterium tuberculosis multiple strains in sputum samples from patients with pulmonary tuberculosis in south western Uganda using MIRU-VNTR. *Sci Rep*. 2022;12(1):1656. <https://www.ncbi.nlm.nih.gov/pubmed/35102181>.
92. Migliori GB, Luna JC, Kurhasani X, Boom MVD, Visca D, D'Ambrosio L, et al. History of prevention, diagnosis, treatment and rehabilitation of pulmonary sequelae of tuberculosis. *Presse Med*. 2022;104112. <https://www.ncbi.nlm.nih.gov/pubmed/35124102>.
93. Modak B, Girkar S, Narayan R, Kapoor S. Mycobacterial Membranes as Actionable Targets for Lipid-Centric Therapy in Tuberculosis. *J Med Chem*. 2022;65(4):3046-65. <https://www.ncbi.nlm.nih.gov/pubmed/35133820>.
94. Mokrousov I, Pasechnik O, Vyazovaya A, Yarusova I, Gerasimova A, Blokh A, et al. Impact of pathobiological diversity of Mycobacterium tuberculosis on clinical features and lethal outcome of tuberculosis. *BMC Microbiol*. 2022;22(1):50. <https://www.ncbi.nlm.nih.gov/pubmed/35135478>.
95. Moore DP, Hesseling AC, Marx FM. Prolonged-course tuberculosis treatment or secondary prevention for those at high risk of recurrence? *Clin Microbiol Infect*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35124263>.
96. Moreira TR, Passos IBJ, Bueno JVL, Maffaccioli R, Colodette RM, Miguel PS. Prevalence of multidrug-resistant tuberculosis in prisons: Systematic review and meta-analysis. *Indian J Med Microbiol*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35120789>.
97. Morel Z, Suarez R, Avalos E, Velazquez S, Martinez F, Lezcano V, et al. Multisystemic inflammatory syndrome related to COVID-19, with latent tuberculosis in bone marrow, and satisfactory response to tocilizumab, in a 7-year-old boy. *Reumatismo*. 2022;73(4). <https://www.ncbi.nlm.nih.gov/pubmed/35130686>.
98. Muhammad SI, Eboreime EA, Ogbonna VI, Zubairu I, Ibisomi L. Clinical guidelines for managing hearing loss as a complication of drug-resistant tuberculosis treatment: an evaluation of implementation fidelity in Kano, Nigeria. *BMC Health Serv Res*. 2022;22(1):142. <https://www.ncbi.nlm.nih.gov/pubmed/35115002>.
99. Muralikrishnan B, Edison LK, Dusthacker A, Jijimole GR, Ramachandran R, Madhavan A, et al. Chrysomycin A inhibits the topoisomerase I of Mycobacterium tuberculosis. *J Antibiot (Tokyo)*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35136191>.
100. Nagot N, Hai VV, Dong TTT, Hai OKT, Rapoud D, Hoang GT, et al. Alarming Tuberculosis Rate Among People Who Inject Drugs in Vietnam. *Open Forum Infect Dis*. 2022;9(2):ofab548. <https://www.ncbi.nlm.nih.gov/pubmed/35106311>.

101. Naidoo A, Naidoo K, Padayatchi N, Dooley KE. Use of integrase inhibitors in HIV-associated tuberculosis in high-burden settings: implementation challenges and research gaps. *Lancet HIV*. 2022;9(2):e130-e8. <https://www.ncbi.nlm.nih.gov/pubmed/35120633>.
102. Nalugwa T, Handley M, Shete P, Ojok C, Nantale M, Reza T, et al. Readiness to implement on-site molecular testing for tuberculosis in community health centers in Uganda. *Implement Sci Commun*. 2022;3(1):9. <https://www.ncbi.nlm.nih.gov/pubmed/35109936>.
103. Nelson KN, Talarico S, Poonja S, McDaniel CJ, Cilnis M, Chang AH, et al. Mutation of Mycobacterium tuberculosis and Implications for Using Whole-Genome Sequencing for Investigating Recent Tuberculosis Transmission. *Front Public Health*. 2021;9:790544. <https://www.ncbi.nlm.nih.gov/pubmed/35096744>.
104. Ngabonziza JCS, Rigouts L, Torrea G, Decroo T, Kamanzi E, Lempens P, et al. Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century. *J Clin Tuberc Other Mycobact Dis*. 2022;27:100299. <https://www.ncbi.nlm.nih.gov/pubmed/35146133>.
105. Niroula N, Lim ZL, Walker S, Huang Y, Gerdt V, Zriba S, et al. Domestic pigs experimentally infected with Mycobacterium bovis and Mycobacterium tuberculosis exhibit different disease outcomes. *Tuberculosis (Edinb)*. 2022;133:102167. <https://www.ncbi.nlm.nih.gov/pubmed/35151010>.
106. Obels I, Ninsiima S, Critchley JA, Huangfu P. Tuberculosis risk among people with diabetes mellitus in Sub-Saharan Africa: a systematic review. *Trop Med Int Health*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35146851>.
107. Ortega J, Infantes-Lorenzo JA, Roy A, de Juan L, Romero B, Moreno I, et al. Factors affecting the performance of P22 ELISA for the diagnosis of caprine tuberculosis in milk samples. *Res Vet Sci*. 2022;145:40-5. <https://www.ncbi.nlm.nih.gov/pubmed/35151157>.
108. Ozkan S. COVID-19 and Tuberculosis: Is It a Syndemic Situation? *Turk Thorac J*. 2021;22(6):512-3. <https://www.ncbi.nlm.nih.gov/pubmed/35110271>.
109. Oztomurcuk D, Terzi O, Demirci C, Kilicaslan Z. Investigation of Granulomatous Inflammations in Terms of Tuberculosis Diagnosis: A 5-Year Multi-center Laboratory Study. *Turk Thorac J*. 2022;23(1):11-6. <https://www.ncbi.nlm.nih.gov/pubmed/35110195>.
110. Panaiotov S, Tolchkov V, Hodzhev Y, Tsafarova B, Trovato A, Cirillo D. Draft Genome Sequences of 77 Endemic Multidrug-Resistant Mycobacterium tuberculosis Strains of SIT41 (TUR) Spoligotype from Bulgaria. *Microbiol Resour Announc*. 2022;11(2):e0111121. <https://www.ncbi.nlm.nih.gov/pubmed/35142538>.
111. Panda S, Faisal S, Kumar K, Seelan DM, Sharma A, Gupta NK, et al. Role of Regulatory Proteins Involved in Iron Homeostasis in Pulmonary Tuberculosis Patients and Their Household Contacts. *Indian J Clin Biochem*. 2022;37(1):77-84. <https://www.ncbi.nlm.nih.gov/pubmed/35125696>.

112. Papasavvas I, Jeannin B, Herbort CP, Jr. Tuberculosis-related serpiginous choroiditis: aggressive therapy with dual concomitant combination of multiple anti-tubercular and multiple immunosuppressive agents is needed to halt the progression of the disease. *J Ophthalmic Inflamm Infect*. 2022;12(1):7. <https://www.ncbi.nlm.nih.gov/pubmed/35132499>.
113. Pattnaik B, Patnaik N, Mittal S, Mohan A, Agrawal A, Guleria R, et al. Micro RNAs as potential biomarkers in tuberculosis: A systematic review. *Noncoding RNA Res*. 2022;7(1):16-26. <https://www.ncbi.nlm.nih.gov/pubmed/35128217>.
114. Pattnaik B, Pb S, Verma M, Kumar S, Mittal S, Arava S, et al. Patient profile and comparison of three diagnostic criteria for cardiac sarcoidosis in a tuberculosis endemic population. *Sarcoidosis Vasc Diffuse Lung Dis*. 2022;38(4):e2021040. <https://www.ncbi.nlm.nih.gov/pubmed/35115747>.
115. Phiza A, Gurpinder S, Simrandeep S, Sushma B. Primary mesenteric gastrointestinal stromal tumour with concomitant mesenteric tuberculosis: Careful histopathology is essential. *Trop Doct*. 2022;494755221076947. <https://www.ncbi.nlm.nih.gov/pubmed/35156872>.
116. Poh XY, Loh FK, Friedland JS, Ong CWM. Neutrophil-Mediated Immunopathology and Matrix Metalloproteinases in Central Nervous System - Tuberculosis. *Front Immunol*. 2021;12:788976. <https://www.ncbi.nlm.nih.gov/pubmed/35095865>.
117. Popoca-Rodriguez I, Cardenas G. Cognitive impairment in patients with central nervous system tuberculosis. *Gac Med Mex*. 2021;157(4):371-6. <https://www.ncbi.nlm.nih.gov/pubmed/35133328>.
118. Priyadarshi M, Arora U, Jorwal P. Extensive intracranial tuberculosis. *Postgrad Med J*. 2022;98(e1):e36. <https://www.ncbi.nlm.nih.gov/pubmed/35105757>.
119. Puranik S, Harlow C, Martin L, Coleman M, Russell G, Park M, et al. Monitoring prolongation of QT interval in patients with multidrug-resistant tuberculosis and non-tuberculous mycobacterium using mobile health device AliveCor. *J Clin Tuberc Other Mycobact Dis*. 2022;26:100293. <https://www.ncbi.nlm.nih.gov/pubmed/35146132>.
120. Puri V, Chaudhary KR, Singh A, Singh C. Inhalation potential of N-Acetylcysteine loaded PLGA nanoparticles for the management of tuberculosis: In vitro lung deposition and efficacy studies. *Curr Res Pharmacol Drug Discov*. 2022;3:100084. <https://www.ncbi.nlm.nih.gov/pubmed/35112077>.
121. Qin R, Wang P, Wang B, Fu L, Batt SM, Besra GS, et al. Identification of thiophene-benzenesulfonamide derivatives for the treatment of multidrug-resistant tuberculosis. *Eur J Med Chem*. 2022;231:114145. <https://www.ncbi.nlm.nih.gov/pubmed/35101648>.
122. Raj R, Sud P, Saharan N, Virk RS. Laryngeal tuberculosis: a neglected diagnosis. *BMJ Case Rep*. 2022;15(2). <https://www.ncbi.nlm.nih.gov/pubmed/35131802>.
123. Ramesh D, Sarkar D, Joji A, Singh M, Mohanty AK, B GV, et al. First-in-class pyrido[2,3-d]pyrimidine-2,4(1H,3H)-diones against leishmaniasis and tuberculosis: Rationale, in vitro, ex vivo studies and mechanistic insights. *Arch Pharm (Weinheim)*. 2022:e2100440. <https://www.ncbi.nlm.nih.gov/pubmed/35106845>.

124. Rashidi HH, Khan IH, Dang LT, Albahra S, Ratan U, Chadderwala N, et al. Prediction of Tuberculosis Using an Automated Machine Learning Platform for Models Trained on Synthetic Data. *J Pathol Inform.* 2022;13:10. <https://www.ncbi.nlm.nih.gov/pubmed/35136677>.
125. Rehman S, Rehman AU, Naveed MA, Iftikhar A. Intracranial and Spinal Tuberculosis: A Rare Entity. *Cureus.* 2021;13(12):e20787. <https://www.ncbi.nlm.nih.gov/pubmed/35111471>.
126. Ritter K, Rousseau J, Holscher C. Interleukin-27 in Tuberculosis: A Sheep in Wolf's Clothing? *Front Immunol.* 2021;12:810602. <https://www.ncbi.nlm.nih.gov/pubmed/35116036>.
127. Rodrigues CC, Neves FL, Cardoso PN. Tuberculosis presenting as erythema nodosum in childhood. *J Paediatr Child Health.* 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35134263>.
128. Rodriguez-Silva CN, Prokopczyk IM, Dos Santos JL. The Medicinal Chemistry of Chalcones as Anti-Mycobacterium tuberculosis Agents. *Mini Rev Med Chem.* 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35156577>.
129. Ruhwald M, Hannay E, Sarin S, Kao K, Sen R, Chadha S. Considerations for simultaneous testing of COVID-19 and tuberculosis in high-burden countries. *Lancet Glob Health.* 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35122718>.
130. Salaikumaran MR, Badiger VP, Burra V. 16S rRNA Methyltransferases as Novel Drug Targets Against Tuberculosis. *Protein J.* 2022;41(1):97-130. <https://www.ncbi.nlm.nih.gov/pubmed/35112243>.
131. Saridakis E, Vishwakarma R, Lai-Kee-Him J, Martin K, Simon I, Cohen-Gonsaud M, et al. Cryo-EM structure of transcription termination factor Rho from Mycobacterium tuberculosis reveals bicyclomycin resistance mechanism. *Commun Biol.* 2022;5(1):120. <https://www.ncbi.nlm.nih.gov/pubmed/35140348>.
132. Scarim CB, Pavan FR. Recent advancement in drug development of nitro(NO₂)-heterocyclic compounds as lead scaffolds for the treatment of Mycobacterium tuberculosis. *Drug Dev Res.* 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35106801>.
133. Schluger NW. Of Mice and Men, Women, and Children: Using Animal Models to Inform Tuberculosis Clinical Trials of Novel Agents. *Am J Respir Crit Care Med.* 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35100099>.
134. Shah I, Antony S, Jaiswal A, Bodhanwala M, Shah D, Tipre P, et al. Feasibility of a "Salvage Regimen" Using Home-based Intravenous Meropenem Therapy With a Delamanid/Bedaquilline Containing Regimen in the Management of MDR/XDR Pediatric Tuberculosis. *Pediatr Infect Dis J.* 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35153288>.
135. Shang L, Li G, Lin Q, Ou M, Liang J, Xiao G, et al. Crystal structure of the cytokinin-producing enzyme "lonely guy" (LOG) from Mycobacterium tuberculosis. *Biochem Biophys Res Commun.* 2022;598:113-8. <https://www.ncbi.nlm.nih.gov/pubmed/35158209>.


136. Sharebiani H, Hajimiri S, Abbasnia S, Soleimanpour S, Hashem Asnaashari AM, Valizadeh N, et al. Game theory applications in host-microbe interactions toward disease manifestation: Mycobacterium tuberculosis infection as an example. *Iran J Basic Med Sci.* 2021;24(10):1324-35. <https://www.ncbi.nlm.nih.gov/pubmed/35096290>.
137. Sharma D, Saini R, Mishra A. Natural phytochemicals physalin D, withaferin a and withanone target L-asparaginase of Mycobacterium tuberculosis: a molecular dynamics study. *J Biomol Struct Dyn.* 2022;1-15. <https://www.ncbi.nlm.nih.gov/pubmed/35132949>.
138. Shen Y, Fang L, Ye B, Xu X, Yu G, Zhou L. The Role of Core Needle Biopsy Pathology Combined with Molecular Tests in the Diagnosis of Lymph Node Tuberculosis. *Infect Drug Resist.* 2022;15:335-45. <https://www.ncbi.nlm.nih.gov/pubmed/35140479>.
139. Shi JC, Wang X, Huang RS, Ning HY, Cai YW, Wu LP, et al. Xpert MTB/RIF Improves the Prognosis of Multidrug-Resistant Tuberculosis Patients Through Faster Diagnosis and Earlier Targeted Treatment: A Prospective Cohort Study. *Microb Drug Resist.* 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35148485>.
140. Shrestha S, Winglee K, Hill A, Shaw T, Smith J, Kammerer JS, et al. Model-based analysis of tuberculosis genotype clusters in the United States reveals high degree of heterogeneity in transmission, and state-level differences across California, Florida, New York, and Texas. *Clin Infect Dis.* 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35143641>.
141. Siddiqui WT, Quentzel H. Gastrointestinal tuberculosis: A mimicker of many. *Travel Med Infect Dis.* 2022;46:102272. <https://www.ncbi.nlm.nih.gov/pubmed/35123067>.
142. Simienh A, Tadesse M, Kebede W, Gashaw M, Abebe G. Combination of Xpert(R) MTB/RIF and Determine™ TB-LAM Ag improves the diagnosis of extrapulmonary tuberculosis at Jimma University Medical Center, Oromia, Ethiopia. *PLoS One.* 2022;17(2):e0263172. <https://www.ncbi.nlm.nih.gov/pubmed/35113917>.
143. Smith CM, Baker RE, Proulx MK, Mishra BB, Long JE, Park SW, et al. Host-pathogen genetic interactions underlie tuberculosis susceptibility in genetically diverse mice. *Elife.* 2022;11. <https://www.ncbi.nlm.nih.gov/pubmed/35112666>.
144. Song J, Du W, Liu Z, Che J, Li K, Che N. Application of Amplicon-Based Targeted NGS Technology for Diagnosis of Drug-Resistant Tuberculosis Using FFPE Specimens. *Microbiol Spectr.* 2022;10(1):e0135821. <https://www.ncbi.nlm.nih.gov/pubmed/35138166>.
145. Squegliaa F, Marasco D, Ruggiero A, Testa G, Esposito L, Berisioa R. Structural and binding properties of the active cell wall hydrolase RipA from M. tuberculosis, a promising biosensing molecule for early warning bacterial detection. *Curr Med Chem.* 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35125077>.
146. Stratman S, Diaz-Perez J, Romanelli P, Lev-Tov H. Development of Chancre-Variant Cutaneous Tuberculosis After BCG Vaccine Administration in a Patient With Migraines. *Wounds.* 2021;33(12):E90-E2. <https://www.ncbi.nlm.nih.gov/pubmed/35100133>.

147. Strong J, Mann TN, Tarr GS, Reuter H. Development of active tuberculosis in patients treated with biological disease-modifying antirheumatic drugs. *S Afr Med J*. 2022;112(2):13498. <https://www.ncbi.nlm.nih.gov/pubmed/35139986>.
148. Stumpf MAM, Kffuri Filho JM, Lichtenstein A. Poncet's disease: a reactive arthritis secondary to pulmonary tuberculosis. *Clin Rheumatol*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35112194>.
149. Sun Q, Shen X, Ma J, Lou H, Sha W. Retraction notice to "LncRNA NEAT1 participates in inflammatory response in macrophages infected by mycobacterium tuberculosis through targeted regulation of miR-377-3p" [Microb. Pathog. (2021) 104674]. *Microb Pathog*. 2022:105406. <https://www.ncbi.nlm.nih.gov/pubmed/35153086>.
150. Sun W, Zhang L, Liang J, Li X, Yang Y, Sun W, et al. Comparison of clinical and imaging features between pulmonary tuberculosis complicated with lung cancer and simple pulmonary tuberculosis: A systematic review and meta-analysis. *Epidemiol Infect*. 2022:1-25. <https://www.ncbi.nlm.nih.gov/pubmed/35105410>.
151. Sundaraiya S, Sulaiman A, Rajendran A. Cardiac Tuberculosis on (18) F-FDG PET Imaging-A Great Masquerader of Cardiac Sarcoidosis. *Indian J Radiol Imaging*. 2021;31(4):1002-7. <https://www.ncbi.nlm.nih.gov/pubmed/35136516>.
152. Suppli CH, Norman A, Folkvardsen DB, Gissel TN, Weinreich UM, Koch A, et al. First outbreak of multi-drug resistant tuberculosis (MDR-TB) in Denmark involving six Danish-born cases. *Int J Infect Dis*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35158061>.
153. Swamy P, Duran C, Gupta A, Misra S, Fredricks K, Cruz AT. Driving to Reduce Socioeconomic Barriers to Latent Tuberculosis Infection Care: A Mobile Pediatric Treatment Program. *J Public Health Manag Pract*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35121709>.
154. Tamirat KS, Kebede FB, Baraki AG, Akalu TY. The Role of GeneXpert MTB/RIF in Reducing Treatment Delay Among Multidrug Resistance Tuberculosis Patients: A Propensity Score Matched Analysis. *Infect Drug Resist*. 2022;15:285-94. <https://www.ncbi.nlm.nih.gov/pubmed/35115796>.
155. Thakur C, Tripathi A, Ravichandran S, Shivananjaiah A, Chakraborty A, Varadappa S, et al. A new blood-based RNA signature (R9), for monitoring effectiveness of tuberculosis treatment in a South Indian longitudinal cohort. *iScience*. 2022;25(2):103745. <https://www.ncbi.nlm.nih.gov/pubmed/35118358>.
156. Thiede JM, Dillon NA, Howe MD, Aflakpui R, Modlin SJ, Hoffner SE, et al. Pyrazinamide Susceptibility Is Driven by Activation of the SigE-Dependent Cell Envelope Stress Response in Mycobacterium tuberculosis. *mBio*. 2022:e0043921. <https://www.ncbi.nlm.nih.gov/pubmed/35100871>.
157. Tong J, Meng L, Bei C, Liu Q, Wang M, Yang T, et al. Modern Beijing sublineage of Mycobacterium tuberculosis shift macrophage into a hyperinflammatory status. *Emerg Microbes Infect*. 2022:1-41. <https://www.ncbi.nlm.nih.gov/pubmed/35125072>.

158. Tornheim JA, Paradkar M, Zhao H, Kulkarni V, Pradhan N, Kinikar A, et al. The Kynurenine/Tryptophan Ratio Is a Sensitive Biomarker for the Diagnosis of Pediatric Tuberculosis Among Indian Children. *Front Immunol.* 2021;12:774043. <https://www.ncbi.nlm.nih.gov/pubmed/35095848>.
159. Tornheim JA, Udwardia ZF, Arora PR, Gajjar I, Sharma S, Karane M, et al. Increased Moxifloxacin Dosing Among Patients With Multidrug-Resistant Tuberculosis With Low-Level Resistance to Moxifloxacin Did Not Improve Treatment Outcomes in a Tertiary Care Center in Mumbai, India. *Open Forum Infect Dis.* 2022;9(2):ofab615. <https://www.ncbi.nlm.nih.gov/pubmed/35097152>.
160. Valencia-Aguirre S, Arroyave I, Garcia-Basteiro AL. Educational level and tuberculosis mortality in Colombia: growing inequalities and stagnation in reduction. *Cad Saude Publica.* 2022;38(1):e00031721. <https://www.ncbi.nlm.nih.gov/pubmed/35107505>.
161. van Heusden P, Mashologu Z, Lose T, Warren R, Christoffels A. The COMBAT-TB Workbench: Making Powerful Mycobacterium tuberculosis Bioinformatics Accessible. *mSphere.* 2022;7(1):e0099121. <https://www.ncbi.nlm.nih.gov/pubmed/35138128>.
162. Vargese SS, Kurian N, Mathew E, Raju AS, Khader J, Pillai RS. Short Comprehensive Multimodal Behavioural Intervention for Tuberculosis-Can It Be Effectively Incorporated in Tribal Health? *J Racial Ethn Health Disparities.* 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35106742>.
163. Varshney D, Singh S, Sinha E, Mohanty KK, Kumar S, Kumar Barik S, et al. Systematic review and meta-analysis of human Toll-like receptors genetic polymorphisms for susceptibility to tuberculosis infection. *Cytokine.* 2022;152:155791. <https://www.ncbi.nlm.nih.gov/pubmed/35158257>.
164. Vasiliu A, Tiendrebeogo G, Awolu MM, Akatukwasa C, Tchakounte BY, Ssekyanzi B, et al. Feasibility of a randomized clinical trial evaluating a community intervention for household tuberculosis child contact management in Cameroon and Uganda. *Pilot Feasibility Stud.* 2022;8(1):39. <https://www.ncbi.nlm.nih.gov/pubmed/35148800>.
165. Vestergaard M, Bald D, Ingmer H. Targeting the ATP synthase in bacterial and fungal pathogens - beyond Mycobacterium tuberculosis. *J Glob Antimicrob Resist.* 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35131507>.
166. Wallis RS, Ginindza S, Beattie T, Arjun N, Likoti M, Sebe M, et al. Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial. *PLoS One.* 2022;17(2):e0252097. <https://www.ncbi.nlm.nih.gov/pubmed/35120127>.
167. Wang W, Liu R, Yao C, Huo F, Shang Y, Zhang X, et al. Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with Disputed rpoB Mutations and Discordant Susceptibility Phenotypes. *Microbiol Spectr.* 2022;10(1):e0208721. <https://www.ncbi.nlm.nih.gov/pubmed/35107324>.

168. Wang Z, Posey DL, Brostrom RJ, Morris SB, Marano N, Phares CR. Post-Arrival Evaluation of Immigrant and Refugee Children in the USA with Latent Tuberculosis Infection Diagnosed Overseas, 2007-2019. *J Pediatr*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35120982>.
169. Wasserman S, Brust JCM, Abdelwahab MT, Little F, Denti P, Wiesner L, et al. Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study. *J Antimicrob Chemother*. 2022. <https://www.ncbi.nlm.nih.gov/pubmed/35134182>.
170. Wei S, Shi B, Zhang J, Li N. Differentiating mass-like tuberculosis from lung cancer based on radiomics and CT features. *Transl Cancer Res*. 2021;10(10):4454-63. <https://www.ncbi.nlm.nih.gov/pubmed/35116302>.
171. Weng F, Meng Y, Lu F, Wang Y, Wang W, Xu L, et al. Differentiation of intestinal tuberculosis and Crohn's disease through an explainable machine learning method. *Sci Rep*. 2022;12(1):1714. <https://www.ncbi.nlm.nih.gov/pubmed/35110611>.
172. Wen-Ting L, Chang-Wei W, De-Jian B, Wei S. Arterial partial pressure of oxygen and procalcitonin levels correlate with pulmonary artery systolic pressure in patients with active pulmonary tuberculosis. *Int J Infect Dis*. 2022;117:87-92. <https://www.ncbi.nlm.nih.gov/pubmed/35121127>.
173. Wijaksono W, Koesoemoprodjo W. Hemorrhagic pleural effusion in Indonesian male with pulmonary tuberculosis: A rare case. *Int J Surg Case Rep*. 2022;91:106800. <https://www.ncbi.nlm.nih.gov/pubmed/35101716>.
174. Wilburn KM, Montague CR, Qin B, Woods AK, Love MS, McNamara CW, et al. Pharmacological and genetic activation of cAMP synthesis disrupts cholesterol utilization in Mycobacterium tuberculosis. *PLoS Pathog*. 2022;18(2):e1009862. <https://www.ncbi.nlm.nih.gov/pubmed/35134095>.
175. Wu Q, Wang M, Zhang Y, Wang W, Ye TF, Liu K, et al. Epidemiological Characteristics and Their Influencing Factors Among Pulmonary Tuberculosis Patients With and Without Diabetes Mellitus: A Survey Study From Drug Resistance Surveillance in East China. *Front Public Health*. 2021;9:777000. <https://www.ncbi.nlm.nih.gov/pubmed/35141185>.
176. Yimcharoen M, Saikaew S, Wattananandkul U, Phunpae P, Intorasoot S, Kasinrerak W, et al. The Regulation of ManLAM-Related Gene Expression in Mycobacterium tuberculosis with Different Drug Resistance Profiles Following Isoniazid Treatment. *Infect Drug Resist*. 2022;15:399-412. <https://www.ncbi.nlm.nih.gov/pubmed/35153492>.
177. Yun HY, Chang V, Radtke KK, Wang Q, Strydom N, Chang MJ, et al. Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis. *Open Forum Infect Dis*. 2022;9(3):ofab660. <https://www.ncbi.nlm.nih.gov/pubmed/35146045>.
178. Zhang Q, Song W, Liu S, An Q, Tao N, Zhu X, et al. An Ecological Study of Tuberculosis Incidence in China, From 2002 to 2018. *Front Public Health*. 2021;9:766362. <https://www.ncbi.nlm.nih.gov/pubmed/35118041>.

179. Zhang S, Li D, Liang L, Tian Z, Sun Z, Jian Y. Clinical Efficacy of CT-Guided Continuous Catheterization Drainage for Spinal Tuberculosis with Large Abscesses. *J Healthc Eng.* 2022;2022:2402048. <https://www.ncbi.nlm.nih.gov/pubmed/35126912>.
180. Zhao J, Gao S, Chen C, Li H, Wang S, Yu Y, et al. Screening and identification of differentially expressed long non-coding RNAs in multidrug-resistant tuberculosis. *PeerJ.* 2022;10:e12776. <https://www.ncbi.nlm.nih.gov/pubmed/35111403>.
181. Zhao P, Chen J, Yang YQ, Peng Y. [Nomogram model for predicting risk of anti-tuberculosis drug-induced liver injury among inpatients with tuberculosis]. *Zhonghua Jie He He Hu Xi Za Zhi.* 2022;45(2):171-6. <https://www.ncbi.nlm.nih.gov/pubmed/35135086>.
182. Zhou X, Lie L, Liang Y, Xu H, Zhu B, Huang Y, et al. GSK-3alpha/beta Activity Negatively Regulates MMP-1/9 Expression to Suppress Mycobacterium tuberculosis Infection. *Front Immunol.* 2021;12:752466. <https://www.ncbi.nlm.nih.gov/pubmed/35095838>.



our other publications...



NIRT Library
National Institute for Research in Tuberculosis
(Indian Council of Medical Research)
1, Mayor Sathyamoorthy Road
Chetpet, Chennai 600031
Tel: 91 44 28369637 | Fax: 91 44 28362525
Email: nirtlibrary@nirt.res.in